Suppr超能文献

皮下注射睾酮治疗:一种安全、实用且合理的选择。

Testosterone Therapy With Subcutaneous Injections: A Safe, Practical, and Reasonable Option.

机构信息

Research Program in Men's Health: Aging and Metabolism, Division of Endocrinology and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Northwestern Medicine McHenry Hospital, Chicago Medical School, Rosalind Franklin University of Medicine and Science, McHenry, IllinoisUSA.

出版信息

J Clin Endocrinol Metab. 2022 Feb 17;107(3):614-626. doi: 10.1210/clinem/dgab772.

Abstract

CONTEXT

Injections with intramuscular (IM) testosterone esters have been available for almost 8 decades and not only result in predictable serum testosterone levels but are also the most inexpensive modality. However, they are difficult to self-administer and associated with some discomfort. Recently, subcutaneous (SC) administration of testosterone esters has gained popularity, as self-administration is easier with this route. Available data, though limited, support the feasibility of this route. Here we review the pharmacokinetics and safety of SC testosterone therapy with both long- and ultralong-acting testosterone esters. In addition, we provide guidance for clinicians on how to counsel and manage their patients who opt for the SC route.

EVIDENCE ACQUISITION

Systematic review of available literature on SC testosterone administration including clinical trials, case series, and case reports. We also review the pharmacology of testosterone absorption after SC administration.

EVIDENCE SYNTHESIS

Available evidence, though limited, suggests that SC testosterone therapy in doses similar to those given via IM route results in comparable pharmacokinetics and mean serum testosterone levels. With appropriate training, patients should be able to safely self-administer testosterone esters SC with relative ease and less discomfort compared with the IM route.

CONCLUSION

Although studies directly comparing the safety of SC vs IM administration of testosterone esters are desirable, clinicians should consider discussing the SC route with their patients because it is easier to self-administer and has the potential to improve patient adherence.

摘要

背景

肌肉内(IM)睾酮酯注射已有近 80 年的历史,不仅能使血清睾酮水平可预测,而且费用最低。但是,它们难以自行注射,且会带来一些不适。最近,睾酮酯的皮下(SC)给药已经变得流行起来,因为这种途径更容易自行给药。虽然数据有限,但可用数据支持这种途径的可行性。本文我们回顾了长作用和超长效睾酮酯的 SC 睾酮治疗的药代动力学和安全性。此外,我们为选择 SC 途径的患者的临床医生提供了关于咨询和管理的指导。

证据获取

对 SC 睾酮给药的现有文献进行系统评价,包括临床试验、病例系列和病例报告。我们还回顾了 SC 给药后睾酮吸收的药理学。

证据综合

尽管证据有限,但可用的证据表明,以与 IM 途径相似的剂量给予的 SC 睾酮治疗会产生相似的药代动力学和平均血清睾酮水平。经过适当的培训,患者应该能够安全地自行 SC 给予睾酮酯,与 IM 途径相比,相对容易且不适感更少。

结论

尽管理想情况下需要直接比较 SC 与 IM 给予睾酮酯的安全性的研究,但临床医生应该考虑与患者讨论 SC 途径,因为它更容易自行给药,并有可能提高患者的依从性。

相似文献

1
Testosterone Therapy With Subcutaneous Injections: A Safe, Practical, and Reasonable Option.
J Clin Endocrinol Metab. 2022 Feb 17;107(3):614-626. doi: 10.1210/clinem/dgab772.
3
Comparison of the Subcutaneous and Intramuscular Estradiol Regimens as Part of Gender-Affirming Hormone Therapy.
Endocr Pract. 2023 May;29(5):356-361. doi: 10.1016/j.eprac.2023.02.006. Epub 2023 Mar 1.
5
Testosterone and other treatments for transgender males and non-binary trans masculine individuals.
Best Pract Res Clin Endocrinol Metab. 2024 Sep;38(5):101908. doi: 10.1016/j.beem.2024.101908. Epub 2024 Jun 25.
6
Testosterone treatment of hypogonadal men participating in competitive sports.
Andrologia. 2008 Jun;40(3):195-9. doi: 10.1111/j.1439-0272.2008.00838.x.
9
Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone.
J Endocr Soc. 2017 Jul 21;1(8):1095-1103. doi: 10.1210/js.2017-00148. eCollection 2017 Aug 1.
10
A mouse model to investigate the impact of testosterone therapy on reproduction in transgender men.
Hum Reprod. 2019 Oct 2;34(10):2009-2017. doi: 10.1093/humrep/dez177.

引用本文的文献

1
Cross-sex hormone therapy in rats induces sex-specific adaptations of renal function and sodium transporters expression.
Front Physiol. 2025 Aug 15;16:1653915. doi: 10.3389/fphys.2025.1653915. eCollection 2025.
2
Assessing the impact of resistance training on renal function of female wistar rats under cross-sex hormone therapy.
Front Physiol. 2025 May 26;16:1543077. doi: 10.3389/fphys.2025.1543077. eCollection 2025.
3
Self-injection experiences among transgender people on injectable gender-affirming hormone therapy: A narrative review.
J Am Pharm Assoc (2003). 2025 Jul-Aug;65(4):102405. doi: 10.1016/j.japh.2025.102405. Epub 2025 Apr 27.
7
Long vs Short Acting Testosterone Treatments: A Look at the Risks.
Urology. 2023 Feb;172:5-12. doi: 10.1016/j.urology.2022.11.016. Epub 2022 Nov 28.
8
A Comparative Analysis of the Common Injections Performed by Plastic Surgeons: 2012 and 2019.
Plast Reconstr Surg Glob Open. 2022 Aug 24;10(8):e4497. doi: 10.1097/GOX.0000000000004497. eCollection 2022 Aug.
9
Pharmacokinetic comparison of three delivery systems for subcutaneous testosterone administration in female mice.
Gen Comp Endocrinol. 2022 Oct 1;327:114090. doi: 10.1016/j.ygcen.2022.114090. Epub 2022 Jun 24.

本文引用的文献

1
Occurrence of Pulmonary Oil Microembolism After Testosterone Undecanoate Injection: A Postmarketing Safety Analysis.
Sex Med. 2020 Jun;8(2):237-242. doi: 10.1016/j.esxm.2020.01.009. Epub 2020 Mar 14.
2
Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study.
J Sex Med. 2019 Nov;16(11):1741-1748. doi: 10.1016/j.jsxm.2019.08.013. Epub 2019 Sep 21.
3
Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial.
J Clin Endocrinol Metab. 2019 Dec 1;104(12):6238-6246. doi: 10.1210/jc.2019-00806.
4
Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate.
J Endocr Soc. 2019 Jun 28;3(8):1531-1540. doi: 10.1210/js.2019-00134. eCollection 2019 Aug 1.
6
Lymphatic System Flows.
Annu Rev Fluid Mech. 2018 Jan;50:459-482. doi: 10.1146/annurev-fluid-122316-045259.
7
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
J Clin Endocrinol Metab. 2018 May 1;103(5):1715-1744. doi: 10.1210/jc.2018-00229.
10
Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone.
J Endocr Soc. 2017 Jul 21;1(8):1095-1103. doi: 10.1210/js.2017-00148. eCollection 2017 Aug 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验